Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maria Carmen Álamo de la Gala"'
Autor:
Encarnación González Flores, Alicia Quílez Cutillas, Alejandro González, Salvador Gámez Casado, Marta Amérigo Góngora, Javier Salvador Bofill, Maria Carmen Álamo de la Gala, Carlos José Rodríguez González, Josefina Cruz Jurado, Pedro Sánchez Rovira, Rocío Urbano Cubero, Rocío Álvarez Ambite, Elisenda Llabrés Valenti, Maria Valero Arbizu, Fernando Henao Carrasco, Manuel Ruiz Borrego, Antonia Martínez Guisado
Publikováno v:
Cancer Research. 80:P1-18
Background: Pertuzumab (P) has been aproved in neoadjuvant setting for HER2 positive early breasta cancer patients in association with Trastuzumab (T) and chemotherapy. Diverse studies support this combination as NeoSphere, Tryphaena, GeparSepto or B
Autor:
Omar A. Araji-Tiliani, José Antonio Marcos-Rodríguez, Antonio Ramón Fernández-López, José M. Barquero-Aroca, María Cinta Calvo-Morón, José Garnacho-Montero, Lara Ferrándiz-Pulido, Natalia Palazón-Carrión, Luis de la Cruz-Merino, Juan Carlos Santos-Jiménez, Lourdes Sevilla-Ortega, Maria Carmen Álamo de la Gala, Ana Agudo Martínez, David Moreno-Ramírez, Rubén de Toro-Salas, José María Jaime-Borrego
Publikováno v:
Cancers, Vol 13, Iss 5485, p 5485 (2021)
Cancers
Cancers
Simple Summary Melanoma still represents a major challenge for health systems around the world. A classical treatment for patients with a high tumor burden or rapidly recurrent in-transit metastases is isolated limb perfusion (ILP) therapy instead of
Autor:
Monica Corral, Juana Maria Oramas Rodriguez, Fernando Garicano Goldaraz, Begoña Campos Balea, Maria Pilar Sancho, Eva Muñoz-Couselo, Maria Carmen Álamo de la Gala, Analia Adela Rodriguez, Javier Medina, Sebastian Ochenduszko, Pedro López Leiva, Guillermo Crespo
Publikováno v:
Journal of Clinical Oncology. 38:e22028-e22028
e22028 Background: The drug combination of BRAF inhibitors with MEK inhibitors delays the onset of resistance and enhances apoptosis. Objectives: The main objective was to evaluate the percentage of long responders to the combination therapy. Methods
Autor:
Marta Amérigo Góngora, Nuria Ribelles, Maria Carmen Álamo de la Gala, Martina Alvarez, Aleix Prat, José M. Jerez, T. Pascual, Aurora Laborda Illanez, Rocío Lavado-Valenzuela, Luis Vicioso, Javier Pascual, Emilio Alba, Cristina Morales-Estevez, Fernando Galvez Montosa, Alejandro Falcon, Tamara Diaz-Redondo, Aranzazu Fernandez, Begona Jimenez Rodriguez, Nuria Chic, Macarena González Guerrero
Publikováno v:
Journal of Clinical Oncology. 36:e12634-e12634
e12634Background: We aim to compare the benefit of adding pertuzumab (P) to the standard neoadjuvant treatment with trastuzumab (T) in patients (pt) with early immunohistochemically (IHC) defined H...
Autor:
Victor Navarro Pérez, Natalia Luque Caro, David Fernández Garay, María Ruiz Sanjuan, Miguel Angel Moreno Jimenez, Pedro López Leiva, Ana Laura Ortega Granados, Capilla de la Torre Cabrera, Maria Carmen Álamo de la Gala, Rosario Dueñas García, Esther Martínez Ortega, Francisco José García Verdejo, Yessica Plata Fernández, Juan Francisco Marín Pozo, Nuria Cárdenas Quesada, Rosa Millán García, Mónica Fernández Navarro, Ana Jaén Morago, Maria Lomas Garrido, Pedro Sánchez Rovira
Publikováno v:
Journal of Clinical Oncology. 35:e20515-e20515
e20515 Background: It is known that outcome of patients included in clinical trials have a better outcome than patients treated with standard therapy. This is a retrospective case-control study of outcome of patients with stage III and IV non-small c
Autor:
Ana María Lozano Barriuso, Natalia Luque Caro, Victor Navarro Pérez, Yessica Plata Fernández, Mónica Fernández Navarro, Esther Martínez Ortega, Nuria Cárdenas Quesada, Ana Jaén Morago, María Ruiz Sanjuan, José Pérez del Palacio, Rosario Dueñas García, Capilla de la Torre Cabrera, Francisca Vicente Pérez, Ana Laura Ortega Granados, Pedro Sánchez Rovira, David Fernández Garay, Francisco José García Verdejo, Maria Carmen Álamo de la Gala, Caridad Díaz Navarro, Olga Genilloud
Publikováno v:
Journal of Clinical Oncology. 35:e15504-e15504
e15504 Background: Perioperative chemotherapy (QT) with platinum and fluoropyrimidines with or without anthracyclines is recommended option in patients with resectable gastric cancer (GC) at least cT2 or nodal involvement. Another option is surgery f
Autor:
Tomás MartÃÂn, Ana Alberto Tamarit, Esther MartÃÂn, Maria Carmen Álamo de la Gala, Luis de la Cruz-Merino, Teresa GarcÃÂa Manrique, Alberto Torres
Publikováno v:
Journal of Clinical Oncology. 33:e17058-e17058
e17058 Background: Nowadays, the use of chemotherapy in the well-differentiated non medullary thyroid cancer, locally advanced stage and/or with radioiodine refractory metastases (Advanced CDT) is ...